Modulating aβ33-42 peptide assembly by graphene oxide.

Area of Science:

• Biomaterials Science
• Nanotechnology
• Neuroscience

Background:

• Amyloid fibrils are implicated in neurodegenerative diseases like Alzheimer's.
• Controlling amyloid beta (Aβ) assembly is crucial for therapeutic development.
• Graphene oxide (GO) possesses unique properties for biomolecular interaction.

Purpose of the Study:

• To investigate the effect of graphene oxide (GO) on amyloid fibril (Aβ33-42) formation.
• To explore GO's potential as a modulator for amyloid assembly pathways.
• To assess the feasibility of graphene-based materials for inhibiting amyloidosis.

Main Methods:

• Utilized graphene oxide (GO) as a modulator for amyloid fibril (Aβ33-42) formation.
• Employed atomic force microscopy (AFM) for temporal evolution measurements.
• Analyzed the initial binding interactions between peptide monomers and GO sheets.

Main Results:

• Graphene oxide (GO) successfully tuned the formation and development of amyloid fibrils (Aβ33-42).
• Atomic force microscopy revealed that GO redirects the amyloid beta assembly pathway.
• Initial peptide monomer binding to GO surfaces significantly influences fibril formation.

Conclusions:

• Graphene oxide acts as an effective modulator of amyloid beta assembly.
• The interaction between GO and peptide monomers offers a strategy to control fibril formation.
• Graphene-based materials show promise for developing novel inhibitors of amyloidosis.